People with a history of cancer should be particularly wary, as IGF-1 (which increases with CJC-1295) may be involved in the development of certain types of cancer
As a dual GLP-1 and GIP receptor agonist, Tirzepatide affects multiple pathways simultaneously: It slows gastric emptying, enhances insulin secretion in a glucose-dependent manner, suppresses glucagon secretion, and powerfully suppresses appetite
GLP-1 agonists are better supported for metabolic anti-aging (reducing obesity, inflammation, and cardiovascular risk)
"Only three small human studies of BPC-157 exist, for instance, the largest of which is a telephone survey of 16 people who received an injection of the drug for knee pain, and which was published in a third-tier journal, Alternative Therapies." I am not sure what is being discussed here
Mukherjee S, Date A, Patravale V, et al
Clinical protocols run $750 to $1,400 for the same duration